An ErbB2-driven breast cancer mouse model (MMTV/Neu) also responded to lapatinib treatment with increased IFNγ driven anti-tumor adaptive immune responses in a STAT1 dependent manner [91]. This evidence concerns the gene ERBB2 and neoplasm.